高能聚焦超声睫状体成形术治疗青光眼的疗效及其影响因素

目的：评估高能聚焦超声睫状体成形术(UCP)治疗青光眼的疗效，并探讨影响疗效的相关因素。

方法：收集天津爱尔眼科医院、重庆爱尔眼科医院、重庆南坪爱尔眼科医院2019-01/2022-01实施UCP治疗患者110例134眼，包括原发性闭角型青光眼、原发性开角型青光眼、继发性青光眼三组患者，记录术后6、12 mo的最佳矫正视力、眼内压，以及使用抗青光眼药物种类等的情况。

结果：术后6 mo，原发性闭角型青光眼组、原发性开角型青光眼组、继发性青光眼组的眼压与术前相比有差异(均P<0.05)。术后12 mo，原发性闭角型青光眼组及原发性开角型青光眼组的眼压与术前相比有差异(均P<0.05)。术后6、12 mo，各组视力与术前相比无差异(均P>0.05)。术后6 mo，眼压变化与年龄、既往青光眼手术史、基线白对白(角膜横径)和UCP治疗扇区有相关性(均P<0.05)。

结论：UCP能有效降低青光眼患者的眼压，其疗效可能受到年龄、既往青光眼手术史、基线白对白(角膜横径)和UCP治疗扇区的影响。UCP对视力没有影响，安全性好。

Efficacy of high-intensity focused ultrasound cycloplasty in glaucoma and its influencing factor

AIM: To evaluate the efficacy of high-intensity focused ultrasound cyclo plasty(UCP)in the treatment of glaucoma and to investigate related influencing factors.

METHODS: The study involved a total of 110 patients(134 eyes)who received UCP treatment between January 2019 and January 2022 at three medical centers: Tianjin Eye Aier Eye Hospital, Chongqing Aier Eye Hospital, and Chongqing Nanping Aier Eye Hospital. Patients were classified into three categories: primary angle-closure glaucoma, primary open-angle glaucoma, and secondary glaucoma. Best corrected visual acuity, intraocular pressure, and the usage of anti-glaucoma medications, etc., were recorded at 6 and 12 mo postoperatively.

RESULTS: After 6 months of the UCP procedure, statistically significant differences in intraocular pressure were observed across all groups(all P<0.05). At 12 mo postoperatively, intraocular pressure of the primary angle-closure and primary open-angle glaucoma groups showed differences(all P<0.05). Notably, there were no significant changes in visual acuity at either the 6 or 12 mo compared to preoperative values across all patient groups(all P>0.05). Furthermore, the study identified a statistically significant correlation between the changes in intraocular pressure at 6 mo and factors such as age, history of previous glaucoma surgery, baseline white-to-white(corneal diameter), and the extent of UCP treatment(all P<0.05).

CONCLUSION: The UCP procedure has been demonstrated to effectively lower intraocular pressure in patients with glaucoma. The efficacy appears to be influenced by variables including patient age, previous glaucoma surgery history, baseline white-to-white(corneal diameter), and the scope of UCP treatment. Importantly, UCP treatment did not adversely affect visual acuity, underscoring its favorable safety profile.